Introduction
Medication compliance rates have been shown to be approximately 50%1-3). About 34% of outpatients who visited a university hospital in Japan were estimated to be medication-noncompliant4).
We performed a survey of medication compliance in outpatients in June 1995, and found that about 70% patients showed complete compliance with the drug regimens prescribed by our hospital physicians5 Among the inpatients who were given pharmaceutical guidance during the hospitalization period, those who often consulted with pharmacists in the outpatient department tended to make fewer mistakes with drug intake after discharge5). These results indicated that more effective pharmaceutical guidance for outpatients is necessary to ensure that they sufficiently understand the usage and dose of drugs, their effects, the importance and aims of treatment, and what to do should they forget to take the drugs. Therefore, we designed a pharmaceutical guidance program for outpatients with several diseases.
Since patients with hyperuricemia have no pain until the occurrence of complications and subjective symptoms, they are insufficiently concerned about their disease and drugs, similarly to other patients with chronic diseases such as hypertension. According to Barlow' s survey, about 30% of patients with gout had renal dysfunction6). Hyperuricemia has been reported to be an independent risk factor of ischemic heart disease and cerebrovascular disease 7-11) . Therefore, it is very important to control and treat hyperuricemia from its subclinical stage. To evaluate the pharmaceutical guidance program for outpatients, we examined the changes in serum uric acid level as a parameter of the compliance of drug intake in patients with hyperuricemia. Patients administered allopurinol, a xanthine oxidase inhibitor, or benzbromarone, widely used as a uric acid eliminant in Japan, were included in this study. These drugs are known to reduce the uric acid levels in hyperuricemic patients and have been shown to have uric acid reducing effects of over 85% for allopurinol, and over 90% for benzbromarone (50 mg/day administration)12-17).
Methods

Subjects
The subjects were patients chosen at random from outpatients diagnosed as having gout or hyperuricemia at the internal or orthopedic departments of our hospital and who were taking allopurinol or benzbromarone. The pharmaceutical guidance program started in October 1997 and ended in June 1998. Each patient gave their consent to participation in the pharmacists' consultation, which was covered by the Japanese health insurance system.
Pharmaceutical guidance program
When drugs were dispensed, the patients were given pharmaceutical guidance as follows, so that they could better understand hyperuricemia and the drugs used to treat their disease. 1. Explanation and confirmation of the usage and dose of drugs. 2. Explanation of the effects of drugs. 3. Explanation of the importance and aims of treatment. 4 . Explanation of what to do should they forget to take the drugs.
5.
Preparation of a drug history notebook for each patient. groups as shown in Table 1 , there were little differences in background between the two groups. Ten patients had hypertension in the intervention group, while 9 had hypertension in the control group. Diuretics, which are considered to affect the uric acid level, had been administered to 5 patients (furosemide in 4 patients, indapamide in 1 patient) in the intervention group and to 3 patients (furosemide in 1 patient, indapamide in 2 patients) in the control group. ACE inhibitors had been administered to 3 patients in the intervention group (enalapril in 2 patients, delapril in 1 patient) and to 4 patients (enalapril in 4 patients) in the control group. There were no differences in the number of drugs administered between the 2 groups (Fisher' s exact test).
Changes in the serum uric acid level
The serum uric acid levels 1 and 6 months after the start of pharmacists' consultation were significantly lower than the baseline level in the intervention group. In the control group, the serum uric acid level remained unchanged 1 and 6 months after the start of pharmacists consultation (Table 2 ). There were no significant differences in the serum uric acid level at the baseline between the two groups, but a difference was observed one month later (p =0. 061). Six months later, the difference in the serum uric acid level between the two groups was significant.
Distribution of the serum uric acid level
Patients were classified into 3 groups based on serum uric acid level i.e. over 7 mg/dL, 5-7 mg/dL, and below 5 mg/dL, according to the previous reports by Tomita et al11) and the definition of the Japan Purine and Pyrimidine Metabolism Association18).
The distributions of the serum uric acid level at baseline and 1 and 6 months after the start of pharmacists' consultation in the intervention group were compared with those in the control group. No significant difference was observed in the baseline between the two groups, while the differences 1 and 6 months after the start of pharmacists' consultation were significant (Fig. 1 ). Fig. 2 shows the changes in serum uric acid levels of individual patients with baseline levels over 7 mg/dL. The uric acid levels invariably showed reduction in the intervention group, while the levels showed inconsistent changes in the control group.
In the intervention group, the doses of uric acid reducing drugs were decreased in 3 patients (allopurinol : 200mg/ day to 100mg/day in 1 patient, benzbromarone : 100mg/ day to 50mg/day in 2 patients). On the other hand, there were no patients in whom the doses were decreased in the control group. In one patient, the dose of allopurinol was increased from 100mg/day to 200mg/day, and benzbromarone was additionally prescribed to 2 patients who had taken allopurinol alone.
Discussion
There was little difference in male : female ratio between the intervention group and control group. So, to confirm the uric acid reducing effects of allopurinol or benzbromarone between female and male, we analyzed the changes in serum uric acid in 24 inpatients ; they were first administered allopurinol or benzbromarone on admission and showed complete compliance. In thirteen female (allopurinol in 10 patients, benzbromarone in 3 patients), serum uric acid level Providing the patient with information about the therapeutic effects of prescribed drugs and early symptoms of their adverse effects helps them understand the effectiveness and safety of prescribed drugs, and thus encourages them to be consciously involved in their own treatment. Under such conditions, pharmacists can feel sure that the patients will take the drugs correctly according to the directions, because they have a better understanding of the prescribed drugs.
According to the pharmaceutical guidance program in this study, prescribed drugs were explained to the patients and recorded in the drug history notebook each time they visited the hospital. The patients could read the records whenever they wanted, and their interest in the drugs increased. The patients' interest in the drugs could be maintained high by repeated explanation using the drug history notebook, and this would improve compliance with drug intake. According to the survey of medication compliance in outpatients, 17. 2% patients frequently asked pharmacist, 47. 4% patients consulted only when they had question in pharmacotherapy, and remaining 35. 4% patients had not consulted with pharmacists, and 72. 2% patients showed complete compliances) . Control group patients of this study might consulted similar frequency and medication compliance as survey.
By maintaining the improved compliance of drug intake by the present program, which was performed by the pharmacists, complications caused by hyperuricemia could be prevented, resulting in a better quality of life (QOL) for the patients. Excess intake of daily total calories, purineenriched food, alcohol beverages and lack of exercise have a significant influence on serum uric acid level. We were also able to have conversations with the patients about the results of the clinical tests, food and drinking behavior, using leaflets explaining hyperuricemia, diet and complications.
The baseline uric acid levels determined in this study probably include those of patients who just started treatment or who received treatment for a very short period, patients who showed non-compliance, and patients whose symptoms were sufficiently controlled. Treatment of hyperuricemia usually aims at controlling the uric acid level to 5 -6 mg/ dL in 3 -6 months. This study period was set at 6 months so that all patients would be treated over 6 months. Although the real end point of hyperuricemia is considered to be prevention of gout attack, joint disorder and renal dysfunction, the serum uric acid level as a parameter of prevention of advancement to these symptoms was used as a surrogate end point in this study. Since Tomita reported that the relative risk of cerebrovascular disorder is significantly lower at uric acid levels below 5 mg/dL11), and the Japan Purine and Pyrimidine Metabolism Association defined the upper limit of normouricemia as under 7 mg/dL'8 , we classified the patients according to uric acid levels as follows : below 5 mg/dL group, 5 -6.9 mg/dL group and over 7 mg/dL group. There were significant differences in the distribution of uric acid levels 1 and 6 months after the start of pharmacists' consultation between the intervention and control groups. It was difficult to understand why the mean uric acid level and the distribution remained unchanged in the control group even though reliable drugs were administered, so we further examined the changes in uric acid level in the 2 groups in more detail. Since patients showing uric acid levels over 7 mg/dL at the baseline were expected to show greater responses to uric acid reducing drugs, the changes in the uric acid level of individual patients showing baseline uric acid levels of over 7 mg/dL were examined. In the intervention group, the uric acid levels were invariably reduced to below 7 mg/dL at 6 months, while the levels showed inconsistent changes in the control group. Although 2 patients in the control group showed reduction of the uric acid level to below 7 mg/dL, these slight decreases were canceled by the changes in the uric acid level in the other patients resulting in the absence of reduction of the mean uric acid level and changes in the distribution. The uric acid levels in the intervention group at baseline should be classified into the close to 7 mg/dL group and 9 to 10mg/dL group. Greater reduction of uric acid level was observed in the 9 to 10mg/dL group. The consistent reduction of uric acid level in the intervention group was probably due to the pharmaceutical guidance program.
Since the drugs used in this study showed reproducible effects, the decrease in the uric acid level observed over the 6 -month period was considered to be the result of good drug compliance. This pharmaceutical guidance program by pharmacists will lead to prevention of complications and maintenance of the patients' QOL. We have begun to use this pharmaceutical guidance program for all patients with hyperuricemia treated in our hospital since July 1998.
